Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psyadon Pharmaceuticals Inc.

www.psyadonrx.com

Latest From Psyadon Pharmaceuticals Inc.

Valbenazine's Consistent But Weak Effect In Tourette Dismays Neurocrine

In "very top-line" Phase IIb data, the magnitude of the treatment effect for valbenazine in children with Tourette syndrome was weaker than expected, and its loss from active development means there will be only a handful of candidates under evaluation for the disorder.

Clinical Trials Neurology

Deal Watch: Harbour Expands Horizons Beyond China

Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.

Deals Business Strategies

Pipeline Watch: Phase III Starts With Durvalumab, Atezolimumab And Eravacycline

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Pfizer licenses therapy for autoimmune diseases

Pfizer is licensing a pre-clinical therapy for patients with rare autoimmune conditions, paying $25 million upfront for what the company sees as a potentially better alternative to a treatment derived from human blood plasma.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ruxton Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Psyadon Pharmaceuticals Inc.
  • Senior Management
  • Richard Chipkon, PhD, Pres. & CEO
  • Contact Info
  • Psyadon Pharmaceuticals Inc.
    Phone: (301) 919-2020
    20451 Seneca Meadows Pkwy.
    Germantown, MD 20876
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register